TARA — Protara Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1359931 ·
Last close
$2.65
Market Cap
$156.60M
52W High
$7.82
52W Low
$2.51
ADV30
1,285,319
Next earnings
2026-11-10

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -23,324,000 -21,668,000 176,093,000 17,076,000 14,782,000
Mar 2026 0 — -19,629,000 -17,782,000 191,923,000 14,737,000 10,715,000
Dec 2025 0 — -19,079,000 -17,307,000 209,468,000 49,657,000 13,056,000
Sep 2025 0 — -14,760,000 -13,258,000 144,636,000 12,551,000 12,345,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-62,995,000
Investing CF
$-95,858,000
Financing CF
$82,129,000
CapEx
$-94,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.34
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-320,201,000
Inventory
—
Receivables
$1,517,000
ST Investments
$121,049,000
EBIT TTM
$-70,054,000
Pretax Income TTM
$-63,307,000
Interest Exp TTM
—
Analysts
7

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -64,549,000 -57,439,000 209,468,000 13,056,000 196,412,000 -56,365,000
Dec 2024 0 -49,154,000 -44,596,000 181,454,000 14,320,000 167,134,000 -35,808,000
Dec 2023 0 -43,613,000 -40,420,000 78,954,000 10,633,000 68,321,000 -37,557,000
Dec 2022 0 -37,545,000 -65,952,000 113,290,000 11,207,000 102,083,000 -26,457,000

TTM Snapshot

Revenues TTM
$6,498,000
NetIncome TTM
$-63,307,000
OpCashFlow TTM
—
Assets (Latest)
$191,923,000
Forward EPS
$-1.69

Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $2.65 · call volume: 116 · put volume: 3
Expected Move to 2027-05-21: ±$1.22 (46.04%) — implied range $1.43 – $3.87 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CRDL Cardiol Therapeutics Inc. $151.87M $1.30 —
ABOS Acumen Pharmaceuticals, Inc. $151.87M $2.10 —
CHRS Coherus Oncology, Inc. $165.32M $1.07 —
IPHA Innate Pharma SA $165.32M $1.48 —
VYGR Voyager Therapeutics, Inc. $146.03M $2.37 —

News headlines (Yahoo Finance, 1h cache)

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 20:05 · Yahoo
What Makes Protara Therapeutics (TARA) a New Buy Stock
2026-07-21 16:00 · Yahoo
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
2026-05-20 12:00 · Yahoo
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
2026-05-15 11:00 · Yahoo
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
2026-04-27 20:05 · Yahoo
One Protara Therapeutics Insider Raised Their Stake In The Previous Year
2026-05-04 10:15 · Yahoo
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
2026-08-11 12:00 · Yahoo
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
2026-05-18 12:00 · Yahoo
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
2026-05-13 12:00 · Yahoo
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
2026-06-23 14:31 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.